North America Clinical Trial Imaging Market Size, Share & Trends Analysis Report By Product and Services (Services, Software), By Application (Oncology, Neurology, Endocrinology, Cardiology, Dermatology, Haematology), By Modality (Computed Tomography, Magnetic Resonance Imaging, Echocardiography, Nuclear Medicine, Positron Emission Tomography, X-Ray, Ultrasound, Optical Coherence Tomography, Others), By End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic and Government Research Institutes, Medical Device Manufacturers, Others) and By Country(US, Canada) Forecasts, 2024-2032

Market Overview

The North America region is expected to reach USD 745 million by 2030 with a CAGR of 5.4%. We are living in an era of rapid advancement in our understanding of human disease.

However, the application of this knowledge in clinical settings has not kept up with the pace of discovery. The process of developing new drugs involves a number of steps, one of which is the conduct of clinical trials. A clinical trial imaging (CTI) study is a research study in which participants participate voluntarily. Each study examines a unique scientific question concerning the usefulness of imaging technologies in detecting illness, diagnosing it, guiding treatment, or monitoring its progress. Imaging techniques for clinical trials can be broken down into the following categories: In general, screening imaging clinical trials ask questions to help researchers determine which type of imaging test will detect disease early, possibly before symptoms appear.

Clinical trials involving diagnostic imaging investigate which types of imaging tests are most likely to effectively detect disease when only a suspicion of disease exists, which types of imaging tests can assist in monitoring a known condition, and which types of imaging tests can monitor the effectiveness of a therapy to determine whether or not it is working. Image-guided interventional clinical trials are designed to evaluate the efficacy of interventions that are guided by imaging.

Imaging techniques are becoming increasingly important in the provision of evidence for decision making in oncological clinical trials. Imaging is still used to define key study end points, even though conventional morphological imaging techniques and standardised response criteria that are based on tumour size measurements have been implemented.

Market Dynamics

Market Drivers

Increasing number of chronic diseases

A physical or mental health condition that lasts more than one year and causes functional restrictions or requires ongoing monitoring or treatment is considered to be a chronic condition. Chronic diseases are some of the most common and expensive health conditions that affect people in the United States. Almost half of all Americans, or about 133 million, have at least one chronic disease and the number has been rising. Chronic diseases, like cancer, diabetes, high blood pressure, stroke, heart disease, respiratory diseases, arthritis, obesity, and oral diseases, can cause hospitalisation, long-term disability, a lower quality of life, and even death. In fact, chronic conditions are the leading cause of death and disability in the United States. This problem will drive the demand of CTI.

Increase in Research & Development

R&D spending and its outcomes Over the last two decades, both R&D spending and the introduction of new drugs have increased. In 2019, the pharmaceutical industry in U.S. spent $83 billion on research and development. When adjusted for inflation, that sum is roughly ten times what the industry spent each year in the 1980s. The number of newly developed medicines that were given the go-ahead to be sold reached a record high of 59 in 2018, marking a 60 percent increase compared to the previous decade in terms of the number of products that were given the green light. This increment would propel the growth in this market.

In addition, in the coming years, an increase in the expansion of a variety of pharmaceutical and biotechnology industries, particularly in economies that are still in the process of developing, would therefore further provide possible future opportunities for the growth of the North America clinical trial imaging market.

Market Restraints

Increasing cost of CTI

The trial is very expensive and the organizations which conduct those trials bear a huge cost because of its high maintenance cost. This factor is expected to impede the growth of this market. In the United States, the costs of phase 1, 2, and 3 clinical trials range from US$1.4-6.6, 7.0-19.6, and 11.5-52.9 million, respectively.

The total cost of a clinical trial is determined by a number of factors, the most important of which are: 

(1) the number of participants and 

(2) the complexity of the clinical trial protocol.

The number of clinical trial participants is highly related to the study phase.

Regional Analysis

The North America clinical trial imaging market report covers the United States, Canada, and Mexico.

Because of its large number of companies and research and development capabilities, the United States dominates the clinical trial imaging market. Furthermore, the emergence of major key players and an increase in government healthcare initiatives will fuel the growth of the North America clinical trial imaging market during the forecast period.

Segmental Analysis

Market for Clinical Trial Imaging market in North America, Broken Down by Product and Services (Services and Software), Application (Oncology, Neurology, Endocrinology, Cardiology, Dermatology, and Haematology, among others), Modality (Computed Tomography, Magnetic Resonance Imaging, Echocardiography, Nuclear Medicine, Positron Emission Tomography, X-Ray, Ultrasound, Optical Coherence Tomography, and Others), End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic and Government Research Institutes, Medical Device Manufacturers, and Others).

Impact of covid-19

Recent Developments

• April 2022, Steve Cutler, CEO of ICON plc, has been named to the first edition of the annual CEO 100 index, which recognises Ireland's top executives.
• April 2022, Clario supports the United Nations Global Compact, pledging to incorporate UN principles into corporate strategy, culture, and day-to-day operations.